WO2010001369A3 - Métodos para el tratamiento y diagnóstico del cáncer - Google Patents

Métodos para el tratamiento y diagnóstico del cáncer Download PDF

Info

Publication number
WO2010001369A3
WO2010001369A3 PCT/IB2009/052936 IB2009052936W WO2010001369A3 WO 2010001369 A3 WO2010001369 A3 WO 2010001369A3 IB 2009052936 W IB2009052936 W IB 2009052936W WO 2010001369 A3 WO2010001369 A3 WO 2010001369A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
chokβ
cancer
treatment
determination
Prior art date
Application number
PCT/IB2009/052936
Other languages
English (en)
French (fr)
Other versions
WO2010001369A2 (es
Inventor
Juan Carlos LACAL SANJUÁN
Ana RAMÍREZ DE MOLINA
David Gallego Ortega
Original Assignee
Translational Cancer Drugs Pharma, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Cancer Drugs Pharma, S.L. filed Critical Translational Cancer Drugs Pharma, S.L.
Priority to CA2729857A priority Critical patent/CA2729857A1/en
Priority to US13/001,637 priority patent/US20110250179A1/en
Priority to BRPI0913943A priority patent/BRPI0913943A2/pt
Priority to MX2011000147A priority patent/MX2011000147A/es
Priority to RU2011142986/10A priority patent/RU2509809C2/ru
Priority to AU2009265121A priority patent/AU2009265121A1/en
Priority to EP09764040A priority patent/EP2316970A2/en
Publication of WO2010001369A2 publication Critical patent/WO2010001369A2/es
Publication of WO2010001369A3 publication Critical patent/WO2010001369A3/es
Priority to US14/509,349 priority patent/US20150098927A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01032—Choline kinase (2.7.1.32)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento del cáncer basados en la inducción de la actividad colina quinasa beta (en adelante ChoKβ) así como a métodos para el diseño de terapias personalizadas y para determinar la respuesta de una gente capaz de inducir colina quinasa beta (en adelante ChoKβ) para el tratamiento del cáncer así como a métodos para determinar el pronóstico de un paciente basados en la determinación de los niveles de expresión de ChoKβ así como basados en la determinación de la relación entre los niveles de expresión de ChoKβ y ChoKα. Por último, la invención se refiere a métodos para determinar la respuesta de un paciente que sufre de cáncer a agentes inhibidores de ChoKα basados en la determinación de los niveles de expresión de PEMT y/o de ChoKβ.
PCT/IB2009/052936 2008-07-04 2009-07-06 Métodos para el tratamiento y diagnóstico del cáncer WO2010001369A2 (es)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2729857A CA2729857A1 (en) 2008-07-04 2009-07-06 Methods for the treatment and diagnosis of cancer
US13/001,637 US20110250179A1 (en) 2008-07-04 2009-07-06 Methods for treatment and diagnosis of cancer
BRPI0913943A BRPI0913943A2 (pt) 2008-07-04 2009-07-06 método para determinar o prognóstico de um paciente que sofre de câncer e composição de agente indutor de atividade de chok(beta)
MX2011000147A MX2011000147A (es) 2008-07-04 2009-07-06 Metodos para el tratamiento y diagnostico del cancer.
RU2011142986/10A RU2509809C2 (ru) 2008-07-04 2009-07-06 Способы лечения и диагностики рака
AU2009265121A AU2009265121A1 (en) 2008-07-04 2009-07-06 Methods for the treatment and diagnosis of cancer
EP09764040A EP2316970A2 (en) 2008-07-04 2009-07-06 Methods for the treatment and diagnosis of cancer
US14/509,349 US20150098927A1 (en) 2008-07-04 2014-10-08 Methods for treatment and diagnosis of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200802007 2008-07-04
ESP200802007 2008-07-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/001,637 A-371-Of-International US20110250179A1 (en) 2008-07-04 2009-07-06 Methods for treatment and diagnosis of cancer
US14/509,349 Continuation US20150098927A1 (en) 2008-07-04 2014-10-08 Methods for treatment and diagnosis of cancer

Publications (2)

Publication Number Publication Date
WO2010001369A2 WO2010001369A2 (es) 2010-01-07
WO2010001369A3 true WO2010001369A3 (es) 2010-04-15

Family

ID=41466389

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/052936 WO2010001369A2 (es) 2008-07-04 2009-07-06 Métodos para el tratamiento y diagnóstico del cáncer

Country Status (8)

Country Link
US (2) US20110250179A1 (es)
EP (1) EP2316970A2 (es)
AU (1) AU2009265121A1 (es)
BR (1) BRPI0913943A2 (es)
CA (1) CA2729857A1 (es)
MX (1) MX2011000147A (es)
RU (1) RU2509809C2 (es)
WO (1) WO2010001369A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012274156A1 (en) * 2011-06-20 2014-01-23 Traslational Cancer Drugs Pharma, S.L. Method for predicting the clinical response to chemotherapy in a subject with cancer
EP2732049A1 (en) * 2011-07-14 2014-05-21 Traslational Cancer Drugs Pharma, S.L. Method for predicting outcome of cancer in a subject
WO2014165216A1 (en) * 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
RU2164419C2 (ru) * 1994-03-18 2001-03-27 Мириад Дженетикс, Инк. Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
HUP0101250A3 (en) 1998-01-29 2006-06-28 Poly Med Inc Anderson Absorbable microparticles
ES2237332B1 (es) 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
CN103215351A (zh) * 2005-04-13 2013-07-24 科学研究高等机关 鉴定用于癌症治疗的化合物的体外方法
US8242081B2 (en) 2005-12-06 2012-08-14 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US20080318234A1 (en) * 2007-04-16 2008-12-25 Xinhao Wang Compositions and methods for diagnosing and treating cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DE MOLINA ET AL: "Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 8, no. 10, 1 October 2007 (2007-10-01), pages 889 - 897, XP022282579, ISSN: 1470-2045 *
LI ZHAOYU ET AL: "Phosphatidylcholine homeostasis and liver failure.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 11 NOV 2005, vol. 280, no. 45, 11 November 2005 (2005-11-11), pages 37798 - 37802, XP007911790, ISSN: 0021-9258 *
RAMIREZ DE MOLINA A ET AL: "Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: Implications in cancer therapy", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, EXETER, GB, vol. 40, no. 9, 1 January 2008 (2008-01-01), pages 1753 - 1763, XP022734731, ISSN: 1357-2725, [retrieved on 20080119] *

Also Published As

Publication number Publication date
RU2509809C2 (ru) 2014-03-20
EP2316970A2 (en) 2011-05-04
MX2011000147A (es) 2011-05-24
CA2729857A1 (en) 2010-01-07
WO2010001369A2 (es) 2010-01-07
BRPI0913943A2 (pt) 2015-10-20
US20110250179A1 (en) 2011-10-13
RU2011142986A (ru) 2013-04-27
AU2009265121A1 (en) 2010-01-07
US20150098927A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
WO2011088149A3 (en) Methods for predicting response of triple-negative breast cancer to therapy
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2010000405A (es) Seleccion de farmacos para terapia de cancer de pulmon usando arreglos a base de anticuerpos.
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
WO2013071119A3 (en) Methods for treating, diagnosing and monitoring alzheimer's disease
WO2009108860A3 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
EP2061907A4 (en) TCL1 EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) REGULATED BY MIR-29 AND MIR-181
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2011135194A3 (en) Method for diagnosing risk of type 1 diabetes and for preventing onset of type 1 diabetes
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
MX344543B (es) Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.
WO2011002834A3 (en) Compositions and methods for diagnosis and treatment of type 1 diabetes
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2011134670A3 (en) Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
WO2014043633A8 (en) Use of e-cadherin and vimentin for selection of treatment responsive patients

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2729857

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/000147

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009265121

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009265121

Country of ref document: AU

Date of ref document: 20090706

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009764040

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13001637

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2011142986

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0913943

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110103